CalciMedica, Inc.
CalciMedica, Inc. (CALC)
Overview
CalciMedica, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California, formed through the March 2023 reverse merger of the former Graybug Vision, Inc. and private CalciMedica. It is a micro-cap development-stage company (market capitalization of roughly $13.5 million as of September 2026, following a 1-for-5 reverse stock split in August 2026) with no approved products and no product revenue. The company is focused on developing therapies for acute, life-threatening inflammatory and immunologic conditions by targeting calcium release-activated calcium (CRAC) channels, a mechanism involved in both inflammatory cascades and direct cellular damage.
What They Do & How They Make Money
CalciMedica does not currently generate revenue from product sales; as a clinical-stage biopharmaceutical company, its business model is to develop drug candidates through clinical trials toward regulatory approval and then generate revenue either by commercializing approved products itself or, more likely given its small size, by licensing or partnering its programs with larger pharmaceutical companies. Its lead candidate, Auxora (zegocractin), is an intravenous CRAC channel inhibitor being studied across multiple acute critical-care indications with high unmet need and, in several cases, no FDA-approved therapy: a Phase 2b trial in acute pancreatitis with systemic inflammatory response syndrome (following a completed Phase 2b CARPO study that showed a 100% relative risk reduction in new-onset severe respiratory failure among medium/high-dose patients), an ongoing Phase 1/2 trial in asparaginase-induced pancreatic toxicity, and a completed Phase 2 trial in COVID-19 pneumonia/ARDS that showed a 56% relative reduction in 30-day mortality versus placebo. A Phase 2 trial in acute kidney injury (KOURAGE) was discontinued in January 2026 after an independent safety signal, though the company states a subsequent review found no evidence of drug-related toxicity. The company also has earlier-stage, currently paused oral CRAC-channel candidates targeting chronic inflammatory conditions such as rheumatoid arthritis and ulcerative colitis. Because it has no approved product, CalciMedica funds its operations through equity financing, including a recently announced $49 million private placement earmarked to advance a pulmonary hypertension program.
Competitors
CalciMedica's 10-K does not name specific competitors, which is typical for a narrowly focused clinical-stage biotech pursuing indications with few or no approved therapies. In practice, the company's most direct "competitor" in several of its target indications (notably acute pancreatitis and asparaginase-induced pancreatic toxicity) is the current standard of care, which is largely supportive care rather than a targeted drug. More broadly, CalciMedica competes for capital, clinical trial sites, and eventual market position against other clinical-stage biotechs developing anti-inflammatory or critical-care therapies, as well as against large pharmaceutical companies (such as Novartis, from whose CRAC-channel inhibitor research CalciMedica's platform originated, and other major players in acute-care and immunology drug development like Regeneron and Roche/Genentech) that could enter the same therapeutic space with far greater resources.
Competitive Position
CalciMedica's key differentiator is a targeted, mechanistically distinct approach (CRAC channel inhibition) aimed at acute, high-mortality conditions — acute pancreatitis, sepsis-related lung injury, and drug-induced pancreatic toxicity — where no approved targeted therapy currently exists, and its early clinical data (large relative risk reductions in respiratory failure and mortality in Phase 2 studies) suggest real potential if confirmed in larger trials. However, the company's competitive position is inherently fragile: it is pre-revenue, has a market capitalization in the low tens of millions of dollars, recently executed a reverse stock split (typically a sign of severe share price pressure), and discontinued one of its lead trials in January 2026 after a safety signal, underscoring the binary, high-risk nature of clinical-stage drug development. Its ability to compete depends almost entirely on continuing to raise dilutive capital to fund trials through to Phase 3 and eventual approval, and on either successfully commercializing Auxora itself or securing a partnership or licensing deal with a larger, better-capitalized pharmaceutical company before its cash runway is exhausted.